NewLink Genetics Corp (NLNK) was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral”. Earlier the firm had a rating of “Buy ” on the company shares. Sun Trust Rbsn Humphrey advised their investors in a research report released on May 11, 2016.
Many Wall Street Analysts have commented on NewLink Genetics Corp. Shares were Reiterated by Stifel on May 10, 2016 to “Buy” and Lowered the Price Target to $ 23 from a previous price target of $63 .Shares were Reiterated by Mizuho on May 10, 2016 to “Buy” and Lowered the Price Target to $ 20 from a previous price target of $52 .Robert W. Baird Initiated NewLink Genetics Corp on Mar 23, 2016 to “Outperform”, Price Target of the shares are set at $27.
NewLink Genetics Corp closed down -5.05 points or -30.61% at $11.45 with 70,71,114 shares getting traded on Tuesday. Post opening the session at $10.81, the shares hit an intraday low of $10.5 and an intraday high of $12.5 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Apr 11, 2016, Charles J. Jr. Link (Chairman of the Board and CEO) sold 10,000 shares at $20.02 per share price. According to the SEC, on Jan 6, 2016, Brian Wiley (VP of Business Development) sold 1,295 shares at $34.73 per share price. On Jan 6, 2016, John B Iii Henneman (EVP, Chief Financial Officer) sold 175 shares at $35.74 per share price, according to the Form-4 filing with the securities and exchange commission.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system’s tolerance to cancer by inhibiting the indoleamine-(2 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.